Advanced search
Publication Cover
Biomarkers in Medicine Volume 7, 2013 - Issue 4
Submit an article Journal homepage
296
Views
0
CrossRef citations to date
0
Altmetric
Review

Progress Towards a Consensus on Biomarkers for Alzheimer‘S Disease: A Review of Peripheral Analytes

Alan Rembach1 The Mental Health Research Institute, The University of Melbourne, Kenneth Myer Building,30 Royal Parade,Parkville, Victoria,3010,AustraliaCorrespondence[email protected]
,
Tim M Ryan1 The Mental Health Research Institute, The University of Melbourne, Kenneth Myer Building,30 Royal Parade,Parkville, Victoria,3010,Australia
,
Blaine R Roberts1 The Mental Health Research Institute, The University of Melbourne, Kenneth Myer Building,30 Royal Parade,Parkville, Victoria,3010,Australia
,
James D Doecke2 The Australian e-Health Research Centre,Herston,Queensland,4029,Australia;3 CSIRO Preventative Health National Research Flagship,North Ryde, New South Wales,2113,Australia
,
William J Wilson3 CSIRO Preventative Health National Research Flagship,North Ryde, New South Wales,2113,Australia
,
Andrew D Watt1 The Mental Health Research Institute, The University of Melbourne, Kenneth Myer Building,30 Royal Parade,Parkville, Victoria,3010,Australia
,
Kevin J Barnham1 The Mental Health Research Institute, The University of Melbourne, Kenneth Myer Building,30 Royal Parade,Parkville, Victoria,3010,Australia
&
Colin L Masters1 The Mental Health Research Institute, The University of Melbourne, Kenneth Myer Building,30 Royal Parade,Parkville, Victoria,3010,Australia
 show all
Pages 641-662 | Published online: 02 Aug 2013

References

  • Barnes DE , YaffeK. The projected effect of risk factor reduction on Alzheimer‘s disease prevalence. Lancet Neurol.10(9), 819–828 (2011).
  • Alzheimer‘s Association. 2012 Alzheimer‘s disease facts and figures. Alzheimers Dement.8(2), 131–168 (2012).
  • Dubois B , FeldmanHH, JacovaCet al. Research criteria for the diagnosis of Alzheimer‘s disease: revising the NINCDS–ADRDA criteria. Lancet Neurol. 6(8), 734–746 (2007).
  • Haass C , SelkoeDJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer‘s amyloid beta-peptide. Nat. Rev. Mol. Cell Biol.8(2), 101–112 (2007).
  • Dinamarca MC , RiosJA, InestrosaNC. Postsynaptic receptors for amyloid-beta oligomers as mediators of neuronal damage in Alzheimer‘s disease. Front. Physiol.3, 464 (2012).
  • Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69(3), 89–95 (2001).
  • Klunk WE . Biological markers of Alzheimer‘s disease. Neurobiol. Aging19(2), 145–147 (1998).
  • Humpel C . Identifying and validating biomarkers for Alzheimer‘s disease. Trends Biotechnol.29(1), 26–32 (2011).
  • Blennow K , HampelH, WeinerM, ZetterbergH. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol.6(3), 131–144 (2010).
  • Marksteiner J , HinterhuberH, HumpelC. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer‘s disease: beta-amyloid(1–42), tau, phospho-tau-181 and total protein. Drugs Today43(6), 423–431 (2007).
  • Peskind ER , RiekseR, QuinnJFet al. Safety and acceptability of the research lumbar puncture. Alzheimer Dis. Assoc. Disord. 19(4), 220–225 (2005).
  • Thambisetty M , LovestoneS. Blood-based biomarkers of Alzheimer‘s disease: challenging but feasible. Biomarkers Med.4(1), 65–79 (2010).
  • Jelic V , HagmanG, YamamotoNGet al. Abnormal platelet amyloid-beta protein precursor (AbetaPP) metabolism in Alzheimer‘s disease: identification and characterization of a new AbetaPP isoform as potential biomarker. J. Alzheimers Dis. 35(2), 285–295 (2013).
  • Casoli T , BaliettiM, GiorgettiB, SolazziM, ScarpinoO, FattorettiP. Platelets in Alzheimer‘s disease-associated cellular senescence and inflammation. Curr. Pharm. Des.19(9), 1727–1738 (2013).
  • Catricala S , TortiM, RicevutiG. Alzheimer disease and platelets: how‘s that relevant. Immun. Ageing9(1), 20 (2012).
  • Hye A , LynhamS, ThambisettyMet al. Proteome-based plasma biomarkers for Alzheimer‘s disease. Brain 129(11), 3042–3050 (2006).
  • Tammen H , SchulteI, HessRet al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 5(13), 3414–3422 (2005).
  • Patel S , ShahRJ, ColemanP, SabbaghM. Potential peripheral biomarkers for the diagnosis of Alzheimer‘s disease. Int. J. Alzheimers Dis.2011, 572495 (2011).
  • Zipser BD , JohansonCE, GonzalezLet al. Microvascular injury and blood–brain barrier leakage in Alzheimer‘s disease. Neurobiol. Aging 28(7), 977–986 (2007).
  • Hye A , LynhamS, ThambisettyMet al. Proteome-based plasma biomarkers for Alzheimer‘s disease. Brain 129(Pt 11), 3042–3050 (2006).
  • Aluise CD , SowellRA, ButterfieldDA. Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer‘s disease. Biochim. Biophys. Acta1782(10), 549–558 (2008).
  • Millioni R , TolinS, PuricelliLet al. High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity. PLoS ONE 6(5), e19603 (2011).
  • Liumbruno G , D‘AlessandroA, GrazziniG, ZollaL. Blood-related proteomics. J. Proteomics73(3), 483–507 (2010).
  • Rogers JT , BushAI, ChoHHet al. Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer‘s disease. Biochem. Soc. Trans. 36(Pt 6), 1282–1287 (2008).
  • Masters CL , CappaiR, BarnhamKJ, VillemagneVL. Molecular mechanisms for Alzheimer‘s disease: implications for neuroimaging and therapeutics. J. Neurochem.97(6), 1700–1725 (2006).
  • Tanzi RE , BertramL. Twenty years of the Alzheimer‘s disease amyloid hypothesis: a genetic perspective. Cell120(4), 545–555 (2005).
  • Selkoe DJ . Alzheimer‘s disease: a central role for amyloid. J. Neuropathol. Exp. Neurol.53(5), 438–447 (1994).
  • Chen M , InestrosaNC, RossGS, FernandezHL. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem. Biophys. Res. Commun.213(1), 96–103 (1995).
  • Haass C , SchlossmacherMG, HungAYet al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359(6393), 322–325 (1992).
  • Mehta PD , PirttilaT, PatrickBA, BarshatzkyM, MehtaSP. Amyloid beta protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci. Lett.304(1–2), 102–106 (2001).
  • Ghersi-Egea JF , GorevicPD, GhisoJ, FrangioneB, PatlakCS, FenstermacherJD. Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J. Neurochem.67(2), 880–883 (1996).
  • Shibata M , YamadaS, KumarSRet al. Clearance of Alzheimer‘s amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier. J. Clin. Invest. 106(12), 1489–1499 (2000).
  • Mayeux R , HonigLS, TangMXet al. Plasma A[beta]40 and A[beta]42 and Alzheimer‘s disease: relation to age, mortality, and risk. Neurology 61(9), 1185–1190 (2003).
  • Giedraitis V , SundelofJ, IrizarryMCet al. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer‘s disease. Neurosci. Lett. 427(3), 127–131 (2007).
  • Fagan AM , MintunMA, ShahARet al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer‘s disease. EMBO Mol. Med. 1(8–9), 371–380 (2009).
  • Wilson MR , YerburyJJ, PoonS. Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mol. Biosyst.4(1), 42–52 (2008).
  • Song F , PoljakA, ValenzuelaM, MayeuxR, SmytheGA, SachdevPS. Meta-analysis of plasma amyloid-beta levels in Alzheimer‘s disease. J. Alzheimers Dis.26(2), 365–375 (2011).
  • Fukumoto H , TennisM, LocascioJJ, HymanBT, GrowdonJH, IrizarryMC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch. Neurol.60(7), 958–964 (2003).
  • Kosaka T , ImagawaM, SekiKet al. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology 48(3), 741–745 (1997).
  • Scheuner D , EckmanC, JensenMet al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer‘s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer‘s disease. Nat. Med. 2(8), 864–870 (1996).
  • Sobow T , FlirskiM, KloszewskaI, LiberskiPP. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer‘s disease. Acta Neurobiol. Exp. (Wars.)65(2), 117–124 (2005).
  • Tamaoka A , FukushimaT, SawamuraNet al. Amyloid beta protein in plasma from patients with sporadic Alzheimer‘s disease. J. Neurol. Sci. 141(1–2), 65–68 (1996).
  • Vanderstichele H , Van KerschaverE, HesseCet al. Standardization of measurement of beta-amyloid(1–42) in cerebrospinal fluid and plasma. Amyloid 7(4), 245–258 (2000).
  • Ertekin-Taner N , YounkinLH, YagerDMet al. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology 70(8), 596–606 (2008).
  • Cosentino SA , SternY, SokolovEet al. Plasma ss-amyloid and cognitive decline. Arch. Neurol. 67(12), 1485–1490 (2010).
  • Sundelof J , GiedraitisV, IrizarryMCet al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch. Neurol. 65(2), 256–263 (2008).
  • van Oijen M , HofmanA, SoaresHD, KoudstaalPJ, BretelerMM. Plasma Abeta(1–40) and Abeta(1–42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol.5(8), 655–660 (2006).
  • Laske C , SopovaK, GkotsisCet al. Amyloid-β peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer‘s disease patients. J. Alzheimers Dis. 21(4), 1263–1269 (2010).
  • Mayeux R , TangMX, JacobsDMet al. Plasma amyloid beta-peptide 1–42 and incipient Alzheimer‘s disease. Ann. Neurol. 46(3), 412–416 (1999).
  • Schupf N , TangMX, FukuyamaHet al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer‘s disease. Proc. Natl Acad. Sci. USA 105(37), 14052–14057 (2008).
  • Lewczuk P , KornhuberJ, VanmechelenEet al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer‘s disease: a multicenter study with multiplexing. Exp. Neurol. 223(2), 366–370 (2010).
  • Pesaresi M , LovatiC, BertoraPet al. Plasma levels of beta-amyloid (1–42) in Alzheimer‘s disease and mild cognitive impairment. Neurobiol. Aging 27(6), 904–905 (2006).
  • Schupf N , ZigmanWB, TangMXet al. Change in plasma Ass peptides and onset of dementia in adults with Down syndrome. Neurology 75(18), 1639–1644 (2010).
  • Seppala TT , HerukkaSK, HanninenTet al. Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J. Neurol. Neurosurg. Psychiatry 81(10), 1123–1127 (2010).
  • Lui JK , LawsSM, LiQXet al. Plasma amyloid-beta as a biomarker in Alzheimer‘s disease: the AIBL study of aging. J. Alzheimers Dis. 20(4), 1233–1242 (2010).
  • Blennow K , De MeyerG, HanssonOet al. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer‘s disease: a multicenter assessment. J. Nutr. Health Aging 13(3), 205–208 (2009).
  • Graff-Radford NR , CrookJE, LucasJet al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol. 64(3), 354–362 (2007).
  • Lambert JC , Schraen-MaschkeS, RichardFet al. Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Neurology 73(11), 847–853 (2009).
  • Yaffe K , WestonA, Graff-RadfordNRet al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305(3), 261–266 (2011).
  • Watt AD , PerezKA, RembachAR, MastersCL, VillemagneVL, BarnhamKJ. Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing. J. Alzheimers Dis.30(2), 323–336 (2012).
  • Fukumoto E , SakaiH, FukumotoS, YagiT, TakagiO, KatoY. Cadherin-related neuronal receptors in incisor development. J. Dent. Res.82(1), 17–22 (2003).
  • Arvanitakis Z , LucasJA, YounkinLH, YounkinSG, Graff-RadfordNR. Serum creatinine levels correlate with plasma amyloid beta protein. Alzheimer Dis. Assoc. Disord.16(3), 187–190 (2002).
  • Kuller LH , LongstrethWTJr, ArnoldAM, BernickC, BryanRN, BeauchampNJ Jr. White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke. Stroke 35(8), 1821–1825 (2004).
  • Lopez OL , KullerLH, MehtaPDet al. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70(19), 1664–1671 (2008).
  • Blasko I , KemmlerG, KramplaWet al. Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy. Neurobiol. Aging 26(8), 1135–1143 (2005).
  • Toledo JB , VandersticheleH, FigurskiMet al. Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathologica 122(4), 401–413 (2011).
  • Rembach A , FauxNG, WattADet al. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer‘s disease. Alzheimers Dement. doi:10.1016/j.jalz.2012.12.006 (2013) (Epub ahead of print).
  • Villemagne VL , PerezKA, PikeKEet al. Blood borne Amyloid-beta dimer correlates with clinical markers of Alzheimer‘s disease. J. Neurosci. 30(18), 6315–6322 (2010).
  • Watt AD , PerezKA, FauxNGet al. Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer‘s disease. J. Alzheimers Dis. 24(1), 47–59 (2010).
  • Pesini P , Perez-GrijalbaV, MonleonIet al. Reliable measurements of the β-amyloid pool in blood could help in the early diagnosis of AD. Int. J. Alzheimers Dis. 604141 (2012).
  • Kiko T , NakagawaK, SatohAet al. Amyloid beta levels in human red blood cells. PLoS ONE 7(11), e49620 (2012).
  • Mattson MP , BegleyJG, MarkRJ, FurukawaK. Abeta25–35 induces rapid lysis of red blood cells: contrast with Abeta1–42 and examination of underlying mechanisms. Brain Res.771(1), 147–153 (1997).
  • Mohanty JG , EckleyDM, WilliamsonJD, LaunerLJ, RifkindJM. Do red blood cell-beta-amyloid interactions alter oxygen delivery in Alzheimer‘s disease?Adv. Exp. Med. Biol.614, 29–35 (2008).
  • Nakagawa K , KikoT, KuriwadaS, MiyazawaT, KimuraF. Amyloid β induces adhesion of erythrocytes to endothelial cells and affects endothelial viability and functionality. Biosci. Biotechnol. Biochem.75(10), 2030–2033 (2011).
  • Kosicek M , HecimovicS. Phospholipids and Alzheimer‘s disease: alterations, mechanisms and potential biomarkers. Int. J. Mol. Sci.14(1), 1310–1322 (2013).
  • Svennerholm L , BostromK, HelanderCG, JungbjerB. Membrane lipids in the aging human brain. J. Neurochem.56(6), 2051–2059 (1991).
  • Bjorkhem I . Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J. Intern. Med.260(6), 493–508 (2006).
  • Pike LJ . The challenge of lipid rafts. J. Lipid Res.50(Suppl.), S323–S328 (2009).
  • Hicks DA , NalivaevaNN, TurnerAJ. Lipid rafts and Alzheimer‘s disease: protein–lipid interactions and perturbation of signaling. Front. Physiol.3, 189 (2012).
  • Pernber Z , BlennowK, BogdanovicN, ManssonJE, BlomqvistM. Altered distribution of the gangliosides GM1 and GM2 in Alzheimer‘s disease. Dement. Geriat. Cogn. Disord.33(2–3), 174–188 (2012).
  • Mahley RW . Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science240(4852), 622–630 (1988).
  • Hoe HS , RebeckGW. Regulated proteolysis of APP and ApoE receptors. Mol. Neurobiol.37(1), 64–72 (2008).
  • Elliott DA , TsoiK, HolinkovaSet al. Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiol. Aging 32(2), 257–271 (2011).
  • Zhou W , ScottSA, SheltonSB, CrutcherKA. Cathepsin D-mediated proteolysis of apolipoprotein E: possible role in Alzheimer‘s disease. Neuroscience143(3), 689–701 (2006).
  • Castano EM , PrelliF, PrasM, FrangioneB. Apolipoprotein E carboxyl-terminal fragments are complexed to amyloids A and L. Implications for amyloidogenesis and Alzheimer‘s disease. J. Biol. Chem.270(29), 17610–17615 (1995).
  • Tolar M , MarquesMA, HarmonyJA, CrutcherKA. Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J. Neurosci.17(15), 5678–5686 (1997).
  • Panegyres PK , GoldblattJ, WalpoleI, ConnorC, LiebeckT, HarropK. Genetic testing for Alzheimer‘s disease. Med. J. Aust.172(7), 339–343 (2000).
  • Akuffo EL , DavisJB, FoxSMet al. The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer‘s disease patients responding to treatment with rosiglitazone. Biomarkers 13(6), 618–636 (2008).
  • Taddei K , ClarnetteR, GandySE, MartinsRN. Increased plasma apolipoprotein E (apoE) levels in Alzheimer‘s disease. Neurosci. Lett.223(1), 29–32 (1997).
  • Lehtimaki T , PirttilaT, MehtaPD, WisniewskiHM, FreyH, NikkariT. Apolipoprotein E (ApoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer‘s disease. Hum. Genet.95(1), 39–42 (1995).
  • Gupta VB , LawsSM, VillemagneVLet al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 76(12), 1091–1098 (2011).
  • Siest G , BertrandP, HerbethBet al. Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses. Clin. Chem. Lab. Med. 38(9), 841–852 (2000).
  • Fukumoto H , IngelssonM, GarevikNet al. APOE epsilon 3/epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer‘s disease diagnosis. Exp. Neurol.183(1), 249–253 (2003).
  • Pfrieger FW . Cholesterol homeostasis and function in neurons of the central nervous system. Cell. Mol. Life Sci.60(6), 1158–1171 (2003).
  • Pitas RE , BoylesJK, LeeSH, HuiD, WeisgraberKH. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J. Biol. Chem.262(29), 14352–14360 (1987).
  • Kivipelto M , NganduT, FratiglioniLet al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol. 62(10), 1556–1560 (2005).
  • Notkola IL , SulkavaR, PekkanenJet al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer‘s disease. Neuroepidemiology 17(1), 14–20 (1998).
  • Whitmer RA , SidneyS, SelbyJ, JohnstonSC, YaffeK. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology64(2), 277–281 (2005).
  • Stewart R , WhiteLR, XueQL, LaunerLJ. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu–Asia Aging Study. Arch. Neurol.64(1), 103–107 (2007).
  • Beydoun MA , Beason-HeldLL, Kitner-TrioloMHet al. Statins and serum cholesterol‘s associations with incident dementia and mild cognitive impairment. J. Epidemiol. Community Health 65(11), 949–957 (2011).
  • Li G , ShoferJB, KukullWAet al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 65(7), 1045–1050 (2005).
  • Mainous AG 3rd, EschenbachSL, WellsBJ, EverettCJ, GillJM. Cholesterol, transferrin saturation, and the development of dementia and Alzheimer‘s disease: results from an 18-year population-based cohort. Fam. Med. 37(1), 36–42 (2005).
  • Romas SN , TangMX, BerglundL, MayeuxR. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology53(3), 517–521 (1999).
  • Tan ZS , SeshadriS, BeiserAet al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch. Intern. Med. 163(9), 1053–1057 (2003).
  • Sato Y , SuzukiI, NakamuraT, BernierF, AoshimaK, OdaY. Identification of a new plasma biomarker of Alzheimer‘s disease using metabolomics technology. J. Lipid Res.53(3), 567–576 (2012).
  • Wong WB , LinVW, BoudreauD, DevineEB. Statins in the prevention of dementia and Alzheimer‘s disease: a meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol. Drug Saf.22(4), 345–358 (2013).
  • Leoni V . Oxysterols as markers of neurological disease – a review. Scand. J. Clin. Lab. Invest.69(1), 22–25 (2009).
  • Hughes TM , RosanoC, EvansRW, KullerLH. Brain cholesterol metabolism, oxysterols, and dementia. J. Alzheimers Dis.33(4), 891–911 (2013).
  • Han X , M HoltzmanD, McKeelDW Jr, KelleyJ, MorrisJC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer‘s disease: potential role in disease pathogenesis. J. Neurochem. 82(4), 809–818 (2002).
  • Cutler RG , KellyJ, StorieKet al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer‘s disease. Proc. Natl Acad. Sci. USA 101(7), 2070–2075 (2004).
  • He X , HuangY, LiB, GongCX, SchuchmanEH. Deregulation of sphingolipid metabolism in Alzheimer‘s disease. Neurobiol. Aging31(3), 398–408 (2010).
  • Han X , RozenS, BoyleSHet al. Metabolomics in early Alzheimer‘s disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS ONE 6(7), e21643 (2011).
  • Mielke MM , HaugheyNJ, Ratnam BandaruVVet al. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement. 6(5), 378–385 (2010).
  • Mielke MM , BandaruVV, HaugheyNJet al. Serum ceramides increase the risk of Alzheimer disease: the Women‘s Health and Aging Study II. Neurology 79(7), 633–641 (2012).
  • Li NJ , LiuWT, LiWet al. Plasma metabolic profiling of Alzheimer‘s disease by liquid chromatography/mass spectrometry. Clin. Biochem. 43(12), 992–997 (2010).
  • Wallin A , GottfriesCG, KarlssonI, SvennerholmL. Decreased myelin lipids in Alzheimer‘s disease and vascular dementia. Acta Neurol. Scand.80(4), 319–323 (1989).
  • Dross K , KewitzH. Concentration and origin of choline in the rat brain. Naunyn Schmiedebergs Arch. Pharmacol.274(1), 91–106 (1972).
  • Igarashi M , MaK, GaoF, KimHW, RapoportSI, RaoJS. Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer‘s disease prefrontal cortex. J. Alzheimers Dis.24(3), 507–517 (2011).
  • Walter A , KorthU, HilgertMet al. Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiol. Aging 25(10), 1299–1303 (2004).
  • Nitsch RM , BlusztajnJK, PittasAG, SlackBE, GrowdonJH, WurtmanRJ. Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl Acad. Sci. USA89(5), 1671–1675 (1992).
  • Ellison DW , BealMF, MartinJB. Phosphoethanolamine and ethanolamine are decreased in Alzheimer‘s disease and Huntington‘s disease. Brain Res.417(2), 389–392 (1987).
  • Molina JA , Jimenez-JimenezFJ, VargasCet al. Cerebrospinal fluid levels of non-neurotransmitter amino acids in patients with Alzheimer‘s disease. J. Neural Transm. 105(2–3), 279–286 (1998).
  • Ginsberg L , RafiqueS, XuerebJH, RapoportSI, GershfeldNL. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer‘s disease brain. Brain Res.698(1–2), 223–226 (1995).
  • Han X , HoltzmanDM, McKeelDWJr. Plasmalogen deficiency in early Alzheimer‘s disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 77(4), 1168–1180 (2001).
  • Han X . Lipid alterations in the earliest clinically recognizable stage of Alzheimer‘s disease: implication of the role of lipids in the pathogenesis of Alzheimer‘s disease. Curr. Alzheimer Res.2(1), 65–77 (2005).
  • Goodenowe DB , CookLL, LiuJet al. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer‘s disease and dementia. J. Lipid Res. 48(11), 2485–2498 (2007).
  • Wood PL , MankidyR, RitchieSet al. Circulating plasmalogen levels and Alzheimer Disease Assessment Scale–Cognitive scores in Alzheimer patients. J. Phychiatry Neurosci. 35(1), 59–62 (2010).
  • Pratico D . The neurobiology of isoprostanes and Alzheimer‘s disease. Biochim. Biophys. Acta1801(8), 930–933 (2010).
  • Lovell MA , MarkesberyWR. Oxidative damage in mild cognitive impairment and early Alzheimer‘s disease. J. Neurosci. Res.85(14), 3036–3040 (2007).
  • Montine TJ , QuinnJ, KayeJ, MorrowJD. F(2)-isoprostanes as biomarkers of late-onset Alzheimer‘s disease. J. Mol. Neurosci.33(1), 114–119 (2007).
  • Pratico D , ClarkCM, LeeVM, TrojanowskiJQ, RokachJ, FitzgeraldGA. Increased 8,12-iso-iPF2alpha-VI in Alzheimer‘s disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol.48(5), 809–812 (2000).
  • Pratico D , ClarkCM, LiunF, RokachJ, LeeVY, TrojanowskiJQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol.59(6), 972–976 (2002).
  • Irizarry MC , YaoY, HymanBT, GrowdonJH, PraticoD. Plasma F2A isoprostane levels in Alzheimer‘s and Parkinson‘s disease. Neurodegene. Dis.4(6), 403–405 (2007).
  • Cooper-Knock J , KirbyJ, FerraiuoloL, HeathPR, RattrayM, ShawPJ. Gene expression profiling in human neurodegenerative disease. Nat. Rev. Neurol.8(9), 518–530 (2012).
  • Booij BB , LindahlT, WetterbergPet al. A gene expression pattern in blood for the early detection of Alzheimer‘s disease. J. Alzheimers Dis. 23(1), 109–119 (2011).
  • Rye PD , BooijBB, GraveGet al. A novel blood test for the early detection of Alzheimer‘s disease. J. Alzheimers Dis. 23(1), 121–129 (2011).
  • Fehlbaum-Beurdeley P , Jarrige-Le PradoAC, PallaresDet al. Toward an Alzheimer‘s disease diagnosis via high-resolution blood gene expression. Alzheimers Dement. 6(1), 25–38 (2010).
  • Lunnon K , SattleckerM, FurneySJet al. A blood gene expression marker of early Alzheimer‘s disease. J. Alzheimers Dis. 33(3), 737–753 (2013).
  • Bellingham SA , GuoBB, ColemanBM, HillAF. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases?Front. Physiol.3, 124 (2012).
  • Sharples RA , VellaLJ, NisbetRMet al. Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J. 22(5), 1469–1478 (2008).
  • Geekiyanage H , JichaGA, NelsonPT, ChanC. Blood serum miRNA: non-invasive biomarkers for Alzheimer‘s disease. Exp. Neurol.235(2), 491–496 (2012).
  • Sheinerman KS , TsivinskyVG, CrawfordF, MullanMJ, AbdullahL, UmanskySR. Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging4(9), 590–605 (2012).
  • Adlard PA , BushAI. Metals and Alzheimer‘s disease. J. Alzheimers Dis.10(2–3), 145–163 (2006).
  • Collingwood JF , MikhaylovaA, DavidsonMet al. In situ characterization and mapping of iron compounds in Alzheimer‘s disease tissue. J. Alzheimers Dis.7(4), 267–272 (2005).
  • Deibel MA , EhmannWD, MarkesberyWR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer‘s disease: possible relation to oxidative stress. J. Neurol. Sci.143(1–2), 137–142 (1996).
  • Lovell MA , RobertsonJD, TeesdaleWJ, CampbellJL, MarkesberyWR. Copper, iron and zinc in Alzheimer‘s disease senile plaques. J. Neurol. Sci.158(1), 47–52 (1998).
  • Miller LM , WangQ, TelivalaTP, SmithRJ, LanzirottiA, MiklossyJ. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer‘s disease. J. Struct. Biol.155(1), 30–37 (2006).
  • Bush AI , TanziRE. Therapeutics for Alzheimer‘s disease based on the metal hypothesis. Neurotherapeutics5(3), 421–432 (2008).
  • Altamura S , MuckenthalerMU. Iron toxicity in diseases of aging: Alzheimer‘s disease, Parkinson‘s disease and atherosclerosis. J. Alzheimers Dis.16(4), 879–895 (2009).
  • Maynard CJ , CappaiR, VolitakisIet al. Overexpression of Alzheimer‘s disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem. 277(47), 44670–44676 (2002).
  • Bellingham SA , CiccotostoGD, NeedhamBEet al. Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts. J. Neurochem. 91(2), 423–428 (2004).
  • White AR , ReyesR, MercerJFet al. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res. 842(2), 439–444 (1999).
  • Bressler JP , OliviL, CheongJH, KimY, MaertenA, BannonD. Metal transporters in intestine and brain: their involvement in metal-associated neurotoxicities. Hum. Exp. Toxicol.26(3), 221–229 (2007).
  • Gerhardsson L , LundhT, MinthonL, LondosE. Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer‘s disease. Dement. Geriat. Cogn. Disord.25(6), 508–515 (2008).
  • Gonzalez C , MartinT, CachoJet al. Serum zinc, copper, insulin and lipids in Alzheimer‘s disease epsilon 4 apolipoprotein E allele carriers. Eur. J. Clin. Invest. 29(7), 637–642 (1999).
  • Roberts NB , CloughA, BelliaJP, KimJY. Increased absorption of aluminium from a normal dietary intake in dementia. J. Inorg. Biochem.69(3), 171–176 (1998).
  • Smorgon C , MariE, AttiARet al. Trace elements and cognitive impairment: an elderly cohort study. Arch. Gerontol. Geriatr. Suppl. (9), 393–402 (2004).
  • Squitti R , BarbatiG, RossiLet al. Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and h-tau. Neurology 67(1), 76–82 (2006).
  • Squitti R , BressiF, PasqualettiPet al. Longitudinal prognostic value of serum ‘free‘ copper in patients with Alzheimer disease. Neurology 72(1), 50–55 (2009).
  • Taylor GA , FerrierIN, McLoughlinIJet al. Gastrointestinal absorption of aluminium in Alzheimer‘s disease: response to aluminium citrate. Age Ageing 21(2), 81–90 (1992).
  • Vural H , DemirinH, KaraY, ErenI, DelibasN. Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer‘s disease. J. Trace Elem. Med. Biol.24(3), 169–173 (2010).
  • Zapatero MD , Garcia de JalonA, PascualF, CalvoML, EscaneroJ, MarroA. Serum aluminum levels in Alzheimer‘s disease and other senile dementias.Biol. Trace Elem. Res.47(1–3), 235–240 (1995).
  • Rossi L , SquittiR, CalabreseL, RotilioG, RossiniPM. Alteration of peripheral markers of copper homeostasis in Alzheimer‘s disease patients: implications in aetiology and therapy. J. Nutr. Health Aging11(5), 408–417 (2007).
  • Squitti R , LupoiD, PasqualettiPet al. Elevation of serum copper levels in Alzheimer‘s disease. Neurology 59(8), 1153–1161 (2002).
  • Bucossi S , VentrigliaM, PanettaVet al. Copper in Alzheimer‘s disease: a meta-analysis of serum, plasma, and cerebrospinal fluid studies. J. Alzheimers Dis. 24(1), 175–185 (2011).
  • Brewer GJ , KanzerSH, ZimmermanEA, CelminsDF, HeckmanSM, DickR. Copper and ceruloplasmin abnormalities in Alzheimer‘s disease. Am. J. Alzheimers Dis. Other Demen.25(6), 490–497 (2010).
  • Molina JA , Jimenez-JimenezFJ, AguilarMVet al. Cerebrospinal fluid levels of transition metals in patients with Alzheimer‘s disease. J. Neural Transm. 105(4–5), 479–488 (1998).
  • Ozcankaya R , DelibasN. Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. Croat. Med. J.43(1), 28–32 (2002).
  • Sedighi BS , M.A, ShariatiM. A study of serum copper and ceruloplasmin in Alzheimer‘s disease in Kerman, Iran. Neurology Asia11, 107–109 (2006).
  • Bocca B , ForteG, PetrucciFet al. Monitoring of chemical elements and oxidative damage in patients affected by Alzheimer‘s disease. Ann. Ist. Super. Sanita 41(2), 197–203 (2005).
  • Squitti R , PasqualettiP, CassettaEet al. Elevation of serum copper levels discriminates Alzheimer‘s disease from vascular dementia. Neurology 60(12), 2013–2014 (2003).
  • Squitti R , PasqualettiP, Dal FornoGet al. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 64(6), 1040–1046 (2005).
  • Squitti R , VentrigliaM, BarbatiGet al. ‘Free‘ copper in serum of Alzheimer‘s disease patients correlates with markers of liver function. J. Neural Transm. 114(12), 1589–1594 (2007).
  • Zappasodi F , SalustriC, BabiloniCet al. An observational study on the influence of the APOE-epsilon4 allele on the correlation between ‘free‘ copper toxicosis and EEG activity in Alzheimer disease. Brain Res. 1215, 183–189 (2008).
  • Arnal N , CristalliDO, De AlanizMJ, MarraCA. Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res. 1319, 118–130 (2010).
  • Rembach A , DoeckeJD, RobertsBRet al. Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer‘s disease. J. Alzheimers Dis. 34(1), 171–182 (2013).
  • Maurer I , ZierzS, MollerHJ. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging21(3), 455–462 (2000).
  • Cottrell DA , BlakelyEL, JohnsonMA, IncePG, TurnbullDM. Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology57(2), 260–264 (2001).
  • De Deyn PP , HiramatsuM, BorggreveFet al. Superoxide dismutase activity in cerebrospinal fluid of patients with dementia and some other neurological disorders. Alzheimer Dis. Assoc. Disord. 12(1), 26–32 (1998).
  • Omar RA , ChyanYJ, AndornAC, PoeggelerB, RobakisNK, PappollaMA. Increased expression but reduced activity of antioxidant enzymes in Alzheimer‘s disease. J. Alzheimers Dis.1(3), 139–145 (1999).
  • Milne DB , JohnsonPE. Assessment of copper status: effect of age and gender on reference ranges in healthy adults. Clin. Chem.39(5), 883–887 (1993).
  • Lewis AJ . The role of copper in inflammatory disorders. Agents Actions15(5–6), 513–519 (1984).
  • Squitti R , QuattrocchiCC, SalustriC, RossiniPM. Ceruloplasmin fragmentation is implicated in ‘free‘ copper deregulation of Alzheimer‘s disease. Prion2(1), 23–27 (2008).
  • Baum L , ChanIH, CheungSKet al. Serum zinc is decreased in Alzheimer‘s disease and serum arsenic correlates positively with cognitive ability. Biometals 23(1), 173–179 (2010).
  • Basun H , ForssellLG, WetterbergL, WinbladB. Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer‘s disease. J. Neural Transm. Park. Dis. Dement. Sect.3(4), 231–258 (1991).
  • Brewer GJ , KanzerSH, ZimmermanEAet al. Subclinical zinc deficiency in Alzheimer‘s disease and Parkinson‘s disease. Am. J. Alzheimers Dis. Other Dement. 25(7), 572–575 (2010).
  • Cornett CR , MarkesberyWR, EhmannWD. Imbalances of trace elements related to oxidative damage in Alzheimer‘s disease brain. Neurotoxicology19(3), 339–345 (1998).
  • Religa D , StrozykD, ChernyRAet al. Elevated cortical zinc in Alzheimer disease. Neurology 67(1), 69–75 (2006).
  • Ahluwalia N , GordonMA, HandteGet al. Iron status and stores decline with age in Lewis rats. J. Nutr. 130(9), 2378–2383 (2000).
  • Strozyk D , LaunerLJ, AdlardPAet al. Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol. Aging 30(7), 1069–1077 (2009).
  • Mueller C , SchragM, CroftonAet al. Altered serum iron and copper homeostasis predicts cognitive decline in mild cognitive impairment. J. Alzheimers Dis. 29(2), 341–350 (2012).
  • Ferretti MT , CuelloAC. Does a pro-inflammatory process precede Alzheimer‘s disease and mild cognitive impairment?Curr. Alzheimer Res.8(2), 164–174 (2011).
  • Strang F , ScheichlA, ChenYCet al. Amyloid plaques dissociate pentameric to monomeric C-reactive protein: a novel pathomechanism driving cortical inflammation in Alzheimer‘s disease? Brain Pathol. 22(3), 337–346 (2012).
  • McGeer EG , McGeerPL. Inflammatory processes in Alzheimer‘s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry27(5), 741–749 (2003).
  • Wyss-Coray T , MuckeL. Inflammation in neurodegenerative disease–a double-edged sword. Neuron35(3), 419–432 (2002).
  • Meyer-Luehmann M , Spires-JonesTL, PradaCet al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer‘s disease. Nature 451(7179), 720–724 (2008).
  • Holmes C , ButchartJ. Systemic inflammation and Alzheimer‘s disease. Biochem. Soc. Trans.39(4), 898–901 (2011).
  • Schwab C , McgeerPL. Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J. Alzheimers Dis.13(4), 359–369 (2008).
  • Walsh SR , CookEJ, GoulderF, JustinTA, KeelingNJ. Neutrophil–lymphocyte ratio as a prognostic factor in colorectal cancer. J. Surg. Oncol.91(3), 181–184 (2005).
  • Sarraf KM , BelcherE, RaevskyE, NicholsonAG, GoldstrawP, LimE. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg.137(2), 425–428 (2009).
  • Kuyumcu ME , YesilY, OzturkZAet al. The evaluation of neutrophil–lymphocyte ratio in Alzheimer‘s disease. Dement. Geriat. Cogn. Disord. 34(2), 69–74 (2012).
  • Imtiaz F , ShafiqueK, MirzaSS, AyoobZ, VartP, RaoS. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int. Arch. Med.5(1), 2 (2012).
  • Leuner K , SchulzK, SchuttTet al. Peripheral mitochondrial dysfunction in Alzheimer‘s disease: focus on lymphocytes. Mol. Neurobiol. 46(1), 194–204 (2012).
  • Swardfager W , LanctotK, RothenburgL, WongA, CappellJ, HerrmannN. A meta-analysis of cytokines in Alzheimer‘s disease. Biol. Psychiatry68(10), 930–941 (2010).
  • Lee KS , ChungJH, ChoiTK, SuhSY, OhBH, HongCH. Peripheral cytokines and chemokines in Alzheimer‘s disease. Dement. Geriat. Cogn. Disord.28(4), 281–287 (2009).
  • Potempa J , KorzusE, TravisJ. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J. Biol. Chem.269(23), 15957–15960 (1994).
  • Gollin PA , KalariaRN, EikelenboomP, RozemullerA, PerryG. Alpha 1-antitrypsin and alpha 1-antichymotrypsin are in the lesions of Alzheimer‘s disease. Neuroreport3(2), 201–203 (1992).
  • Liao PC , YuL, KuoCC, LinC, KuoYM. Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer‘s disease. Proteomics Clin. Appl.1(5), 506–512 (2007).
  • Sihlbom C , DavidssonP, SjogrenM, WahlundLO, NilssonCL. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer‘s disease patients and healthy individuals. Neurochem. Res.33(7), 1332–1340 (2008).
  • Nielsen HM , MinthonL, LondosEet al. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69(16), 1569–1579 (2007).
  • Choi J , MalakowskyCA, TalentJM, ConradCC, GracyRW. Identification of oxidized plasma proteins in Alzheimer‘s disease. Biochem. Biophys. Res. Commun.293(5), 1566–1570 (2002).
  • Yu HL , ChertkowHM, BergmanH, SchipperHM. Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics3(11), 2240–2248 (2003).
  • Sun YX , MinthonL, WallmarkA, WarkentinS, BlennowK, JanciauskieneS. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer‘s disease. Dement. Geriat. Cogn. Disord.16(3), 136–144 (2003).
  • Nuutinen T , SuuronenT, KauppinenA, SalminenA. Clusterin: a forgotten player in Alzheimer‘s disease. Brain Res. Rev.61(2), 89–104 (2009).
  • Kim N , HanJY, RohGSet al. Nuclear clusterin is associated with neuronal apoptosis in the developing rat brain upon ethanol exposure. Alcohol. Clin. Exp. Res. 36(1), 72–82 (2012).
  • Lambert JC , HeathS, EvenGet al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer‘s disease. Nat. Genet. 41(10), 1094–1099 (2009).
  • Seshadri S , FitzpatrickAL, IkramMAet al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303(18), 1832–1840 (2010).
  • Harold D , AbrahamR, HollingworthPet al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer‘s disease. Nat. Genet. 41(10), 1088–1093 (2009).
  • Schrijvers EM , KoudstaalPJ, HofmanA, BretelerMM. Plasma clusterin and the risk of Alzheimer disease. JAMA305(13), 1322–1326 (2011).
  • Thambisetty M , SimmonsA, VelayudhanLet al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch. Gen. Psychiatry 67(7), 739–748 (2010).
  • Silajdzic E , MinthonL, BjorkqvistM, HanssonO. No diagnostic value of plasma clusterin in Alzheimer‘s disease. PLoS ONE7(11), e50237 (2012).
  • Hu Y , HosseiniA, KauweJSet al. Identification and validation of novel CSF biomarkers for early stages of Alzheimer‘s disease. Proteomics Clin. Appl. 1(11), 1373–1384 (2007).
  • Kalaria RN , GoldeT, KroonSN, PerryG. Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer‘s disease. Am. J. Pathol.143(3), 886–893 (1993).
  • Akiyama H , IkedaK, KondoH, McGeerPL. Thrombin accumulation in brains of patients with Alzheimer‘s disease. Neurosci. Lett.146(2), 152–154 (1992).
  • Ho GJ , SmirnovaIV, AkaabouneM, HantaiD, FestoffBW. Serine proteases and their serpin inhibitors in Alzheimer‘s disease. Biomed Pharmacother.48(7), 296–304 (1994).
  • Pike CJ , VaughanPJ, CunninghamDD, CotmanCW. Thrombin attenuates neuronal cell death and modulates astrocyte reactivity induced by beta-amyloid in vitro. J. Neurochem.66(4), 1374–1382 (1996).
  • Mhatre M , NguyenA, KashaniS, PhamT, AdesinaA, GrammasP. Thrombin, a mediator of neurotoxicity and memory impairment. Neurobiol. Aging25(6), 783–793 (2004).
  • Okazaki T , YanagisawaY, NagaiT. Analysis of the affinity of each haptoglobin polymer for hemoglobin by two-dimensional affinity electrophoresis. Clin. Chim. Acta258(2), 137–144 (1997).
  • Sadrzadeh SM , GrafE, PanterSS, HallawayPE, EatonJW. Hemoglobin. A biologic fenton reagent. J. Biol. Chem.259(23), 14354–14356 (1984).
  • Gutteridge JM . The antioxidant activity of haptoglobin towards haemoglobin-stimulated lipid peroxidation. Biochim. Biophys. Acta917(2), 219–223 (1987).
  • Abraham JD , Calvayrac-PawlowskiS, CoboSet al. Combined measurement of PEDF, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer‘s disease and other dementias. Biomarkers 16(2), 161–171 (2011).
  • Zhang R , BarkerL, PinchevDet al. Mining biomarkers in human sera using proteomic tools. Proteomics 4(1), 244–256 (2004).
  • Johnson G , BraneD, BlockWet al. Cerebrospinal fluid protein variations in common to Alzheimer‘s disease and schizophrenia. Appl. Theor. Electrophor. 3(2), 47–53 (1992).
  • Mattila KM , PirttilaT, BlennowK, WallinA, ViitanenM, FreyH. Altered blood–brain-barrier function in Alzheimer‘s disease?Acta Neurol. Scand.89(3), 192–198 (1994).
  • Brown RC , HanZ, CascioC, PapadopoulosV. Oxidative stress-mediated DHEA formation in Alzheimer‘s disease pathology. Neurobiol. Aging24(1), 57–65 (2003).
  • Rammouz G , LecanuL, AisenP, PapadopoulosV. A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: the biochemical basis for a diagnosis of Alzheimer‘s disease. J. Alzheimers Dis.24(Suppl. 2), 5–16 (2011).
  • Taurines R , DudleyE, GrasslJet al. Proteomic research in psychiatry. J. Psychopharmacol. 25(2), 151–196 (2011).
  • Lista S , FaltracoF, PrvulovicD, HampelH. Blood and plasma-based proteomic biomarker research in Alzheimer‘s disease. Prog. Neurobiol.101–102, 1–17 (2013).
  • Cutler P , AkuffoEL, BodnarWMet al. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: two novel biomarkers of Alzheimer‘s disease in human plasma. Proteomics Clin. Appl. 2(4), 467–477 (2008).
  • Johnstone D , MilwardEA, BerrettaR, MoscatoP. Multivariate protein signatures of pre-clinical Alzheimer‘s disease in the Alzheimer‘s disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS ONE7(4), e34341 (2012).
  • Song F , PoljakA, SmytheGA, SachdevP. Plasma biomarkers for mild cognitive impairment and Alzheimer‘s disease. Brain Res. Rev.61(2), 69–80 (2009).
  • Kawarabayashi T , ShojiM. Plasma biomarkers of Alzheimer‘s disease. Curr. Opin. Psychiatry21(3), 260–267 (2008).
  • Ray S , BritschgiM, HerbertCet al. Classification and prediction of clinical Alzheimer‘s diagnosis based on plasma signaling proteins. Nat. Med. 13(11), 1359–1362 (2007).
  • Soares HD , ChenY, SabbaghM, RoherA, SchrijversE, BretelerM. Identifying early markers of Alzheimer‘s disease using quantitative multiplex proteomic immunoassay panels. Ann. NY Acad. Sci.1180, 56–67 (2009).
  • Marksteiner J , KemmlerG, WeissEMet al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer‘s disease. Neurobiol. Aging 32(3), 539–540 (2011).
  • Rocha de Paula M , Gómez RavettiM, BerrettaR, MoscatoP. Differences in abundances of cell-signalling proteins in blood reveal novel biomarkers for early detection of clinical Alzheimer‘s disease. PLoS ONE 6(3), e17481 (2011).
  • O‘Bryant SE , XiaoG, BarberRet al. A blood-based screening tool for Alzheimer‘s disease that spans serum and plasma: findings from TARC and ADNI. PLoS ONE 6(12), e28092 (2011).
  • Doecke JD , LawsSM, FauxNGet al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch. Neurol. 69(10), 1318–1325 (2012).
  • Soares HD , PotterWZ, PickeringEet al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch. Neurol. 69(10), 1310–1317 (2012).
  • Bazenet C , LovestoneS. Plasma biomarkers for Alzheimer‘s disease: much needed but tough to find. Biomarkers Med.6(4), 441–454 (2012).
  • Kraemer S , VaughtJD, BockCet al. From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay. PLoS ONE 6(10), e26332 (2011).
  • Galimberti D , GhezziL, ScarpiniE. Immunotherapy against amyloid pathology in Alzheimer‘s disease. J. Neurol. Sci. doi:10.1016/j.jns.2012.12.013 (2013) (Epub ahead of print).
  • Manzone TA , DamHQ, SoltisD, SagarVV. Blood volume analysis: a new technique and new clinical interest reinvigorate a classic study. J. Nucl. Med. Technol.35(2), 55–63; quiz 77, 79 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.